Active substanceAlprostadilAlprostadil
Similar drugsTo uncover
  • Alprostan® Zentiva
    concentrate d / infusion 
    Zentiva c.s.     Czech Republic
  • Arters-Vero®
    lyophilizate d / infusion 
    VEROPHARM SA     Russia
  • Vazaprostan®
    lyophilizate d / infusion 
    YUSB Pharma GmbH     Germany
  • Vazaprostan®
    lyophilizate d / infusion 
    YUSB Pharma GmbH     Germany
  • VAP® 20
    concentrate d / infusion 
  • VAP 500
    concentrate d / infusion 
  • Kaverdzhekt®
    lyophilizate in / cavern. 
  • Dosage form: & nbsplyophilizate for the preparation of a solution for intracavernous administration
    Composition:

    1 bottle with lyophilizate contains:

    The active substance: alprostadil - 11.9 μg or 23.5 μg.

    Excipients: lactose monohydrate (in terms of lactose) - 194 mg, sodium citrate dihydrate (in terms of sodium citrate) - 53 μg, alfadex - 386/763 μg, hydrochloric acid concentrated to pH 3.5-6.0. sodium hydroxide to pH 3.5-6.0.

    1 ml of solvent contains:

    Benzyl alcohol-9 mg, water for injection-up to 1 ml.

    Description:

    Lyophilizate: a lyophilized powder of white or almost white color.

    Solvent is a clear, colorless liquid with a faint smell of benzyl alcohol.

    Reconstituted solution: clear, colorless liquid.

    Pharmacotherapeutic group:Vasodilating agent - prostaglandin E1, analog synthetic
    ATX: & nbsp

    G.04.B.E.01   Alprostadil

    Pharmacodynamics:

    Alprostadil is an analogue of in natural conditionsaboutrma of prostaglandin E1, which has a wide range of pharmacological effects. Among its most significant effects are vasodilation and suppression of platelet aggregation.

    With intracavernous injection alprostadil inhibits α 1 -adrenoreceptors in tissues, relaxes the musculature of cavernous bodies, increases blood flow and improves microcirculation. Alprostadil causes an erection by relaxation of the trabecular smooth muscles of the cavernous bodies and dilatation of the cavernous arteries, which leads to the expansion of the lacunar spaces and the closure of the blood flow by pressing the venules against the protein membrane (occlusion of the penis veins).

    The onset of action is 5-10 minutes, duration - 1-3 hours.

    Pharmacokinetics:

    Absorption

    For the treatment of erectile dysfunction alprostadil intracavernously introduced into the cavernous bodies of the penis. Absolute bioavailability of alprostadil is not defined.

    Distribution

    After intracavernous injection of 20 μg of alprostadil, the average peripheral plasma concentrations 30 and 60 minutes after injection (89 and 102 picograms / mL, respectively) were not significantly higher than the levels of endogenous alprostadil

    (96 picograms / ml). Alprostadil binds to plasma proteins, primarily with albumin (81%) and to a lesser extent with the fraction IV-4 α-globulin (55%). Essential binding with erythrocytes or leukocytes was not observed.

    Metabolism

    Alprostadil quickly turns into compounds, which in turn are metabolized before excretion from the body. About 80 % of circulating alprostadil Metabolized at the first passage through the lungs, mainly through beta and omega-oxidation. The primary metabolites of alprostadil are 15-keto-PGE1 13,14-dihydro-15-oxo-PGE1 and 13,14-dihydro-PGE1 Unlike the 15-keto-PGE1 and 13,14-dihydro-15-oxo-PGE1 which are almost completely devoid of biological activity, 13,14-dihydro-PGE1 lowers blood pressure and suppresses platelet aggregation. After intracavernous administration of alprostadil, the levels of this metabolite are of the same order as the levels of PGE1, at the same time, the levels of 13,14-dihydro-15-oxo-PGE1 the main circulating metabolite, more than 10 times higher. 15-keto-PGE1 is not found in the plasma throughout the observation period. After intracavernous injection of 20 μg of alprostadil, the content of the main circulating metabolite 13,14-dihydro-15-oxo-PGE1 in the peripheral blood flow increases and reaches a maximum after 30 minutes, and then returns to the baseline level 60 minutes after administration, while the levels of alprostadil in the peripheral blood flow remain slightly higher than the baseline. The concentration of 13,14-dihydro-PGE1 in plasma is not determined.

    Excretion

    Metabolites of alprostadil are excreted mainly by the kidneys, almost 90 % The intravenous dose is excreted in the urine within 24 hours. The rest is excreted with feces.

    The influence of age or race

    The possible influence of age or race on the pharmacokinetics of alprostadil after intra-cavernous administration was not evaluated.

    Long-term studies of the carcinogenicity of alprostadil were not conducted.

    There was no potential mutagenicity of alprostadil.

    Alprostadil in a dose of up to 2 mg / kg / day, administered subcutaneously, does not affect reproductive function and does not cause changes in spermatogenesis.

    Indications:

    Violations of the erection of neurogenic, vascular, psychogenic or mixed etiology. Diagnosis of erectile dysfunction in addition to other diagnostic tests.

    Contraindications:

    Established hypersensitivity to the components of the drug, as well as lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

    Diseases that can predispose to priapism, such as sickle cell anemia, myeloma, leukemia.

    Anatomic deformities of the penis (angulation of the penis, cavernous fibrosis, Peyronie's disease, urethral stricture, hypospadias). Presence of a penile implant

    Men who are contraindicated or not recommended sex life.

    Age to 18 years and old age (over 75 years).

    Carefully:

    Thrombocytopenia, polycythemia, thrombophlebitis, urethritis, balanitis, venous thrombosis (including predisposition), increased blood viscosity.

    Dosing and Administration:

    Intracavernous injection. It is recommended to use a needle size of 27-30 G, length of 13 mm. The injection site is the dorso-lateral part of the proximal third of the penis.

    Selection of the initial dose in the doctor's office

    The dose is selected individually for each patient by careful titration under the supervision of a doctor. The following scheme should be followed, taking into account the erectile response, until the dose that causes an erection is sufficient for a sexual intercourse, but not more than 60 minutes. If there is no response to a specific dose, then the next higher dose can be administered after 1 hour. If there is an answer, the interval between doses should be at least day. The patient should be in the doctor's office until come complete detumescentsiya.


    Neurogenic etiology (Damage

    dorsal

    brain)

    Vascular, psychogenic and mixed etiology

    Initial

    injection

    1.25 μg

    2.5 μg

    The second

    injection

    2.5 μg

    With partial response to the first

    injection: 5 μg

    In the absence of an answer: 7.5 μg

    The third

    injection

    5 μg

    With the subsequent increase in the dose of 5-10 μg

    Value

    step by step

    increasing the dose to

    achievements

    optimal dose

    5 μg

    5 -10 μg

    Supportive therapy

    The dose chosen for self-injection should cause the patient to have an erection sufficient for a sexual intercourse, with a duration of no more than 1 hour.

    If the duration of the erection exceeds 1 hour, then the dose should be reduced.Self-treatment at home should begin with a dose set in the doctor's office. If necessary, the dose should be changed only after consultation with the doctor and in accordance with the instructions for selection of a dose. The lowest effective dose should be given. The recommended frequency of injections is no more than three times a week, but not more than once a day. The erection usually comes in 5-20 minutes after the injection.

    The average dose of alprostadil at the end of the 6 month of therapy was 20.7 μg. In most patients, the maintenance dose was 5-20 μg. Doses over 60 μg are not recommended.

    Additional tool for diagnosis of erectile dysfunction

    In the simplest trial for erectile dysfunction (pharmacological test) after intracavernous administration of the drug Kaverdzhekt®, the patient develops an erection. Kaverdzhekt® is also used in addition to laboratory studies, such as duplex or Doppler ultrasound, xenon-133 washout, radioisotope phallography, and penile arteriography, which allows visualization and assessment of the condition of the vessels of the penis.In any case, you should use a single dose of the drug Kaverdzhekt®, which causes a normal erection.

    Breeding and self-introduction procedure

    For breeding use only Supplied solvent or water for injection with benzyl alcohol 0.9%. After dilution in 1 ml of solvent, the volume of the resulting solution is 1.13 ml. In 1 ml of this solution, the vials with a dosage of 10 μg and 20 μg will contain 10.5 μg or 20.5 μg of alprostadil, respectively, but after injection, 10 μg or 20 μg of alprostadil will enter the body, respectively, because 0.5 μg is lost due to adsorption on the walls of the syringe and vial. After dilution of the drug should not be added to the bottle any substances.

    Before administration, the solution must be visually checked for particles or discoloration.

    1. Wash your hands with soap and water.

    2. Remove the plastic protective cap from the bottle.

    3. Using one of the attached alcohol impregnated wipers, wipe the rubber stopper of the bottle (the second napkin will be needed later). The used tissue should be discarded.

    4. Unpack the large needle with the marking 22G1V2, not removing from it at the same plastic protective cap. Connect the needle to the syringe by gently screwing it into the thread.

    5. Carefully remove the protective cap from the needle.

    Fig.1

    6. Holding the syringe with the tip of the needle up, bring the syringe piston to the "1 ml" mark (to remove excess water from the syringe.)

    7. Push the rubber stopper of the vial into the center of the bottle and press the piston down to insert water into the vial.

    8. Gently holding the syringe and the vial as one unit, with gentle circular motions, achieve complete dissolution of the powder. Do not use the drug if the resulting solution is cloudy, or has become stained, or contains any particles.

    9. Turn the bottle upside down without removing the syringe. After making sure that the needle tip is located below the liquid level, slowly pull the syringe piston toward yourself until the solution level reaches the mark corresponding to the chosen dose.

    10. To remove air bubbles, tap the syringe lightly, or put the solution back into the vial, and then slowly re-dial it into the syringe.

    11. Remove the needle from the bottle and gently place the protective cap on it

    12. Open the package with a smaller needle (30G1/2), but do not get the needle, but put the package aside.

    13 Remove the larger needle from the syringe with the protective cap and set aside to discard.

    1. Holding a syringe in one hand, take a smaller sized needle from the opened package, without removing the plastic protective cap from it, and connect it to the syringe, as a larger needle was connected.

    Fig. 2.

    The transverse section of the penis shows the injection site.

    Veins, arteries, nerves

    Cavernous bodies (two)

    Locations injection: needle insertion in one of the cavernous bodies

    Urethra

    Fig. 3.

    Sexual penis, top view: injection sites are shaded.

    Places holding injections

    The drug should be injected into one of the two areas of the penis, which are called cavernous bodies.

    15. Carry out the procedure for self-introduction the drug should be in the sitting position, standing or reclining.

    16. Injections should be performed only at the locations indicated in Fig. 2 and 3. Avoid entering the visible veins. Repeated injections should be performed alternately on one side of the penis. Each time, you should choose a new point on the corresponding side for injection.

    17. Take the glans penis with the thumb and forefinger. Pull out the penis and hold it firmly with your fingers so that during the procedure it does not slip out.Men who have not undergone circumcision (excision of the foreskin) should remove the foreskin in order to determine precisely the site of the injection.

    18. Thoroughly treat the skin at the injection site with an unused cloth impregnated with alcohol. Put this napkin aside.

    19. Take the syringe with your thumb and forefinger, without placing your thumb on the piston. With a firm movement, insert the needle at an angle of 90 degrees to the injection site indicated by the doctor.

    Fig. 4. Inserting the needle into the injection site.

    1. Use your thumb or forefinger to press the plunger. With slow confident movement, enter the entire contents of the syringe.
    2. Remove the needle from the penis.

    While holding the penis on both sides, press the napkin, soaked in alcohol, to the place of injection and hold it for about 3 minutes. If there is blood, then you should press the napkin until the bleeding stops.

    1. After using the contents of this package, all materials should be discarded, adhering to the relevant safety rules.
    Side effects:

    Local - (most often): pain and burning in the penis, prolonged erection (duration 4-6 hours), fibrosis of the penis, bruising and ecchymosis at the injection site.

    Fibrosis of the penis, including angulation of the penis, the formation of fibrous nodules and Peyronie's disease are noted in 3-8% of patients. Hematoma at the injection site (3% of patients) and ecchymosis at the injection site (2 % patients) are more likely associated with injection technique than with alprostadil. The frequency of prolonged erection (4-6 hours) was 4 %.

    Local (less than 1%): priapism (duration of an erection more than 6 hours), balanitis, hemorrhages at the injection site, inflammation, itching and swelling at the injection site, bleeding from the urethra, sensation of warmth in the penis, numbness, fungal infection, irritation, hypersensitivity, phimosis, erythema, "venous discharge" from cavernous bodies, painful erection, ejaculation disorder.

    The frequency of priapism was 0.4%. In most cases, spontaneous relaxation of the penis was observed.

    System effects (most often): increased blood pressure, dizziness, headache, back pain, upper respiratory tract infection, flu-like syndrome, sinusitis, nasal congestion, cough, prostatitis.

    Systemic effects (less than 1%): pain in the testes, swelling of the testicles,sensation of warmth in the testes, thickening of the testicles, reddening of the scrotum, pain in the scrotum, spermatoceles, swelling of the scrotum, hematuria, impaired urination, increased urination, mandatory urination, pain in the pelvic region, lowering of the blood pressure, tachycardia, vasodilation, peripheral vascular disorders, supraventricular extrasystole, vasovagal reactions, hypoesthesia, muscle weakness, hyperhidrosis, rash, nausea, dry mouth, increased serum creatinine level, calf muscle cramps, pupillary dilatation.

    Decrease in blood pressure and increased heart rate were observed at doses of the drug more than 20 μg and 30 μg, respectively, and, apparently, were dose-dependent. However, these changes were not clinically significant; Only 3 patients stopped treatment because of lowering blood pressure.

    Kaverdzhekt® did not have a clinically significant effect on the results of a laboratory study of blood and urine.

    Overdose:

    Symptoms: pain in the penis, prolonged erection and / or priapism, irreversible deterioration of erectile function.

    Treatment: If the erection lasts less than 6 hours, medical supervision is necessary,as spontaneous detumescence occurs (cessation of erection, decrease in the size of the genital organs due to outflow of blood), if more than 6 hours, an intracavernous injection of α-adrenomimetics (for example, ephedrine, epinephrine, phenylephrine, ethyl ether) or aspirate blood from cavernous bodies or perform a surgical treatment. The patient must be under medical observation to the disappearance of systemic phenomenath and / or before the full detemescence of the penis.
    Interaction:

    Kaverdzhekt® is not intended for mixing or simultaneous administration with other drugs, and also for joint use with other drugs for the treatment of erectile dysfunction. The possibility of pharmacokinetic interactions with other drugs has not been investigated. Joint use with antihypertensive drugs, diuretics, antidiabetic drugs (including insulin), or non-steroidal anti-inflammatory drugs does not have any effect on the safety or efficacy of the drug Kaverdzhekt.The safety and efficacy of the co-administration of Kaverdzhekt® with other vasoactive drugs has not been studied.

    The presence of gasoline alcohol in the solvent reduces the degree of binding to the walls of the vial. In this regard, when using water for injection containing gasoline alcohol, a more stable solution is obtained and a more complete administration of the preparation is provided.

    Special instructions:

    Before the beginning of therapy with the drug Kaverdzhekt®, diagnosis of the causes of erectile dysfunction should be performed.

    The first injection of the drug. should be conducted in the doctor's office by specially trained medical personnel. Self-injection can only begin after a detailed briefing of the patient and mastering the technique of self-injection. The doctor should carefully evaluate the patient's skills and his ability to perform this procedure. Intracavernous administration should be carried out in accordance with the rules of asepsis. Continuous monitoring of the patient's self-administered condition should be carried out, especially in the initial period, when a dose change may be required.Every 3 months the patient is recommended to visit the attending physician to assess the effectiveness and safety of treatment and dose adjustment (if necessary). The bottle with the diluted preparation is intended for single use and is discarded after use. The patient should be instructed on the rules for the destruction of the needle, syringe and vial.

    It is known that after intra-cavernous introduction of vasoactive drugs, including Kaverdzhekt®, priapism may develop (an erection lasting more than 6 hours). To reduce the risk of priapism, the lowest effective dose should be given. The patient should immediately inform the doctor about all cases of erection lasting more than 4 hours. Treatment of priapism is conducted in accordance with established medical practice.

    After intracavernous administration of the drug, penile fibrosis can develop, including penile angulation, formation of fibrous nodules and Peyronie's disease. The incidence of fibrosis may increase with increasing duration of drug use. To identify signs of fibrosis of the penis or Peyronie's disease, regular examination of patients with a close examination of the penis is strongly recommended.In patients with development of penile angulation, cavernous fibrosis or Peyronie's disease, treatment with the drug should be discontinued.

    Since intracavernous injection may cause minor bleeding, patients using Cavageject® should be aware of the protection measures against sexually transmitted infections and also through blood, including human immunodeficiency virus (HIV). Patients receiving treatment with anticoagulants such as warfarin or heparin have an increased tendency to bleed after intracavernous injection.

    Special control is necessary in patients receiving monoamine oxidase inhibitors, and in case of prolonged erection in patients treated with α-adrenomimetics (hypertensive crisis may develop); as well as in patients with coronary heart disease, chronic heart failure or pulmonary disease (sexual stimulation and sexual intercourse can lead to an exacerbation of the disease).

    It is not recommended to be used in patients with a tendency to addiction and / or with mental or intellectual disabilities (to prevent misuse of the drug).It is necessary to strictly observe the compliance of the used dosage form of alprostadil with specific indications for its use.

    Form release / dosage:Lyophilizate for the preparation of a solution for intracavernous administration of 10 mcg, 20 mcg.
    Packaging:

    Lyophilizate for the preparation of a solution for intracavernous administration complete with a solvent (0.9% solution of benzene alcohol). By 10 μg or 20 μg of lyophilizate per bottle of clear colorless hydrolysis resistant glass class 1 (Hept. F.), sealed with a bromobutyl rubber stopper, coated with an aluminum cap with a protective plastic lid.

    For 1 ml of solvent in a disposable syringe colorless resistant to hydrolysis glass class 1 (Hept. F.).

    1 vial with lyophilizate, 1 syringe with solvent, 2 needles (22G 1 1/2 and 30G 1/2).

    2 impregnated with alcohol wipes together with instructions for use are placed in a cardboard box.

    Storage conditions:

    At a temperature of no higher than 25 ° C. Do not freeze.

    The reconstituted solution should be stored in the original vial at a temperature of 2 to 8 ° C for a maximum of 24 hours.

    Do not freeze or cool.

    Keep out of the reach of children.

    Shelf life:

    Shelf life: 2 years.

    Shelf life of the solvent: 3 years.

    Shelf life of the reconstituted solution is no more than 24 hours.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015497 / 01
    Date of registration:03.03.2009
    The owner of the registration certificate:Pfizer IFG Belgium N.V.Pfizer IFG Belgium N.V. Belgium
    Manufacturer: & nbsp
    Representation: & nbspPfizer LtdPfizer LtdUSA
    Information update date: & nbsp21.08.2015
    Illustrated instructions
    Instructions
    Up